Jens Rose Fogh
2100 København Ø
H. Lundbeck A/S is developing new antibody based drugs against targets within the brain. Only ~0.1 % of the mAbs given intravenously are able to pass the blood brain barrier and be distributed in the cerebrospinal fluid (CSF). The quantification on mAbs in CSF therefore requires state-of-the-art equipment with unparalleled sensivity and the ability to distinguish between therapeutic and endogenous proteins.
This industrial PhD project is focused on developing new LC-MS based methods for quantifying mAbs and biomarkers related to alzheimer's disease in CSF as well as plasma and brain tissue.
Primary fields of research
- Quantification of mAbs with LC-MS/MS.
- Peptide mapping using HRMS.
- Development of new sensitive methods for analyzing CSF samples.
- Quantification of biomarkers associated with Alzheimer's disease.